USFDA conducts GCP inspection at Syngene International Ltd's facility at Semicon Park, Bengaluru

The United States Food and Drug Administration (USFDA) conducted a Good Clinical Practices (GCP) compliance inspection of Syngene International Limited's facility at Semicon Park, Bengaluru, from June 09, 2025, to June 13, 2025. The inspection concluded successfully, with the facility found to be in compliance with the required regulations. The inspection resulted in zero observations and no Form 483 was issued. The inspection has been classified as No Action Indicated (NAI).

The company remains commitment to high operating standards and rigorous compliance with global regulatory requirements across all its operations.

Shares of Syngene International Limited was last trading in BSE at Rs. 652.50 as compared to the previous close of Rs. 662.90. The total number of shares traded during the day was 11391 in over 649 trades.

The stock hit an intraday high of Rs. 661.60 and intraday low of 651.05. The net turnover during the day was Rs. 7467496.00.

Source : Equity Bulls

Keywords

SyngeneInternational INE398R01022 Pharmaceuticals USFDA GCPInspection SemiconPark Bengaluru NoObservations NoForm483